
Cabaletta Bio ( ($CABA) ) just unveiled an update. On November 9, 2026, Cabaletta reported new Phase 1/2 rese-cel data presented at the American College of Rheumatology Convergence 2026. The
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CABA | Cabaletta Bio | 1.01 | -1.05 | -50.93% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.01 | -50.93% |

Cabaletta Bio ( ($CABA) ) just unveiled an update. On November 9, 2026, Cabaletta reported new Phase 1/2 rese-cel data presented at the American College of Rheumatology Convergence 2026. The

Citi lowered the firm’s price target on Cabaletta Bio (CABA) to $8 from $10 and keeps a Buy rating on the shares. The firm updated the company’s model post the

Cabaletta Bio (CABA) announced new Phase 1/2 clinical data on resecabtagene autoleucel, rese-cel, to be presented in one oral and two poster presentations at the American College of Rheumatology, ACR,

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Cabaletta Bio. The associated price target remains the same with $16.00. Douglas Tsao’s rating is based on several

Cabaletta Bio (CABA) announced that registrational adult topline results from RESET-Myositis are anticipated in the second half of 2027, with a planned Biologics License Application submission in the first quarter

Shares in Caribou Biosciences ($CRBU) plunged over 43% today as investors reacted to the company’s decision to potentially put itself up for sale and slash jobs because of a lack

Cabaletta Bio ( ($CABA) ) has provided an update. Cabaletta Bio, a biotechnology company developing engineered immune cell therapies for autoimmune and other serious diseases, continues to focus on patients

“A single infusion of rese-cel has demonstrated the potential to deliver deep, clinical responses after discontinuation of all immunomodulators with up to 1.5 years of follow-up as reported in the

High‑risk, high-reward stocks can swing sharply, but they can also deliver big gains when their strategy plays out. Analysts are bullish about a few small names that belong to fast‑moving

Cabaletta Bio, Inc. ($CABA) announced an update on their ongoing clinical study. RESET-MS: CABA Halts Multiple Sclerosis CAR-T Trial Before First Dose RESET-MS was planned to test a new cell
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Sep 2, 2026 | ||||
| buy | Reiterated | Aug 14, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 | ||||
| buy | Reiterated | Mar 23, 2026 | ||||
| hold | Reiterated | Dec 17, 2025 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 18, 2027TBA | $227.59M | $-0.27 | $0.00 | 0.04 | -0.74 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.